On September 12, a press conference was held at the press center of the Interfax News Agency in Ekaterinburg, dedicated to the epidemiological situation, as well as new research on the treatment of acute respiratory viral infections in children in the Sverdlovsk Region. At the moment, multicenter, randomized, double-blind, comparative, placebo-controlled clinical trials of the efficacy and safety of Triazavirin in 12-17 year old children with ARVI diagnosis have been completed.
Visit the website of the Triazavirin drug for more details